Microbiota-gut-brain axis and toll-like receptors in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a multifactorial disease which involves both the periphery and central nervous system (CNS). It has been recently recognized that gut microbiota interacts with the gut and brain (microbiota-gut-brain axis), contributing to the pathogenesis of neurodegenerative diseases, such as AD. Dysbiosis of gut microbiota can induce increased intestinal permeability and systemic inflammation, which may lead to the development of AD pathologies and cognitive impairment via the neural, immune, endocrine, and metabolic pathways. Toll-like receptors (TLRs) play an important role in the innate immune system via recognizing microbes-derived pathogens and initiating the inflammatory process. TLRs have also been found in the brain, especially in the microglia, and have been indicated in the development of AD. In this review, we summarized the relationship between microbiota-gut-brain axis and AD, as well as the complex role of TLRs in AD. Intervention of the gut microbiota or modulation of TLRs properly might emerge as promising preventive and therapeutic strategies for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941
Bravo, J. A., Forsythe, P., Chew, M. V., Escaravage, E., Savignac, H. M., Dinan, T. G., Bienenstock, J., & Cryan, J. F. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102999108 · Cited by 3,888 · cited 1×
“in vagotomized mice, suggesting the vagus as a modulatory communication pathway between the gut and brain [88].”
BackgroundGut microbiota composition correlates with diet and health in the elderly
Claesson, M. J., Jeffery, I. B., Conde, S., Power, S. E., O’Connor, E. M., Cusack, S., Harris, H. M. B., Coakley, M., Lakshminarayanan, B., O’Sullivan, O., et al. (2012) · Nature · doi:10.1038/nature11319 · Cited by 3,314 · cited 1×
“The diversity and configuration of microbiota in the elderly can be affected by factors including residence location, diet, and health status, leading to the incidence of a wide variety of aging-related diseases [81,82].”
BackgroundThe gut microbiota influences blood-brain barrier permeability in mice
Braniste, V., Al-Asmakh, M., Kowal, C., Anuar, F., Abbaspour, A., Tóth, M., Korecka, A., Bakocevic, N., Ng, L. G., Kundu, P., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009759 · Cited by 2,530
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease
Pickard, J. M., Zeng, M. Y., Caruso, R., & Núñez, G. (2017) · Immunological Reviews · doi:10.1111/imr.12567 · Cited by 1,699 · cited 1×
“Gut microbiota not only has metabolic and trophic functions, but also promotes host defense and immune homeostasis [29,30].”
BackgroundPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
The interplay between the intestinal microbiota and the brain
Collins, S. M., Surette, M., & Bercik, P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2876 · Cited by 1,611 · cited 1×
“endocrine, and metabolic signals, which is regarded as the microbiota-gut-brain axis [27].”
BackgroundPasolli, E., Asnicar, F., Manara, S., Zolfo, M., Karcher, N., Armanini, F., Beghini, F., Manghi, P., Tett, A., Ghensi, P., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.001 · Cited by 1,591
Antibiotics, birth mode, and diet shape microbiome maturation during early life
Bokulich, N. A., Chung, J., Battaglia, T., Henderson, N., Jay, M., Li, H., D. Lieber, A., Wu, F., Perez-Perez, G. I., Chen, Y., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7121 · Cited by 1,469
Self-citationBell, R. D., Winkler, E. A., Sagare, A. P., Singh, I., LaRue, B., Deane, R., & Zlokovic, B. V. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.043 · Cited by 1,448 · cited 1×
“However, BBB dysfunction and leakage, associated with tight junction impairment and pericytes loss, are common during aging [84,85].”
BackgroundCattaneo, A., Cattane, N., Galluzzi, S., Provasi, S., Lopizzo, N., Festari, C., Ferrari, C., Guerra, U. P., Paghera, B., Muscio, C., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.08.019 · Cited by 1,382
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Wang, X., Sun, G., Feng, T., Zhang, J., Huang, X., Wang, T., Xie, Z., Chu, X., Yang, J., Wang, H., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0216-x · Cited by 1,144 · cited 2×
“A drug named GV-971, remodeled the gut microbiota, could reduce Th1 cell proliferation in the blood and harness neuroinflammation and cognitive impairment, which has also been demonstrated effective in a phase 3 clinical trial [126].”
BackgroundSystemic inflammation and disease progression in Alzheimer disease
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bb95 · Cited by 1,139 · cited 1×
“infarction and so on, could boost neuroinflammation and exaggerate cognitive decline [24].”
BackgroundRisk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Yassour, M., Vatanen, T., Siljander, H., Hämäläinen, A.-M., Härkönen, T., Ryhänen, S. J., Franzosa, E. A., Vlamakis, H., Huttenhower, C., Gevers, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad0917 · Cited by 1,043
Jakobsson, H. E., Abrahamsson, T. R., Jenmalm, M. C., Harris, K., Quince, C., Jernberg, C., Björkstén, B., Engstrand, L., & Andersson, A. F. (2014) · Gut · doi:10.1136/gutjnl-2012-303249 · Cited by 1,011 · cited 1×
“Gut microbiota transmission occurs during the peri-partum period from mothers to their infants, which could be affected by several perturbations, including birth by Cesarean section and the use of antibiotics during pregnancy [73,74].”
BackgroundIntestinal barrier and gut microbiota: Shaping our immune responses throughout life
Takiishi, T., Fenero, C. I. M., & Câmara, N. O. S. (2017) · Tissue Barriers · doi:10.1080/21688370.2017.1373208 · Cited by 1,009
Akbari, E., Asemi, Z., Daneshvar Kakhaki, R., Bahmani, F., Kouchaki, E., Tamtaji, O. R., Hamidi, G. A., & Salami, M. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00256 · Cited by 946
Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats
Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Björklund, T., Wang, Z.-Y., Roybon, L., Melki, R., & Li, J.-Y. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1343-6 · Cited by 925
Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota
Harach, T., Marungruang, N., Duthilleul, N., Cheatham, V., Mc Coy, K. D., Frisoni, G., Neher, J. J., Fåk, F., Jucker, M., Lasser, T., et al. (2017) · Scientific Reports · doi:10.1038/srep41802 · Cited by 901 · cited 1×
“The altered microbial composition could influence the levels of Ab42, amyloid deposition, and pro-inflammatory cytokines in the brain [99].”
BackgroundGut Microbiota is Altered in Patients with Alzheimer’s Disease
Zhuang, Z.-Q., Shen, L.-L., Li, W.-W., Fu, X., Zeng, F., Gui, L., Lü, Y., Cai, M., Zhu, C., Tan, Y.-L., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180176 · Cited by 885
McGeer, P. L., Itagaki, S., Tago, H., & McGeer, E. G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90696-3 · Cited by 836 · cited 1×
“As early as in the 1990s, microglia had been revealed can be activated by Ab [44,45].”
BackgroundThe Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Eimer, W. A., Vijaya Kumar, D. K., Navalpur Shanmugam, N. K., Rodriguez, A. S., Mitchell, T., Washicosky, K. J., György, B., Breakefield, X. O., Tanzi, R. E., & Moir, R. D. (2018) · Neuron · doi:10.1016/j.neuron.2018.06.030 · Cited by 674
Minter, M. R., Zhang, C., Leone, V., Ringus, D. L., Zhang, X., Oyler-Castrillo, P., Musch, M. W., Liao, F., Ward, J. F., Holtzman, D. M., et al. (2016) · Scientific Reports · doi:10.1038/srep30028 · Cited by 655 · cited 1×
“chemokines, which coincided with attenuated Ab plaque deposition and neuroinflammatory responses [104].”
BackgroundCD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar Aβ-Stimulated Microglial Activation
Reed-Geaghan, E. G., Savage, J. C., Hise, A. G., & Landreth, G. E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3158-09.2009 · Cited by 591
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567
Role of the Toll-Like Receptor 4 in Neuroinflammation in Alzheimer’s Disease
Walter, S., Letiembre, M., Liu, Y., Heine, H., Penke, B., Hao, W., Bode, B., Manietta, N., Walter, J., Schulz-Schüffer, W., et al. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000110455 · Cited by 543
Protective effects of NSAIDs on the development of Alzheimer disease
Vlad, S. C., Miller, D. R., Kowall, N. W., & Felson, D. T. (2008) · Neurology · doi:10.1212/01.wnl.0000311269.57716.63 · Cited by 535
Gram-negative bacterial molecules associate with Alzheimer disease pathology
Zhan, X., Stamova, B., Jin, L.-W., DeCarli, C., Phinney, B., & Sharp, F. R. (2016) · Neurology · doi:10.1212/wnl.0000000000003391 · Cited by 521 · cited 1×
“Higher bacterial LPS level was found in AD brains than that of the controls [113].”
BackgroundMoresco, E. M. Y., LaVine, D., & Beutler, B. (2011) · Current Biology · doi:10.1016/j.cub.2011.05.039 · Cited by 500 · cited 1×
“TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11 are expressed on the plasma membrane, which recognize microbial products such as lipids, lipoproteins, and proteins, whereas TLR3, TLR7, TLR8, and TLR9 are localized in cytoplasmic compartments, which can be activated by nucleic acid species [34].”
BackgroundTLR2 Is a Primary Receptor for Alzheimer’s Amyloid β Peptide To Trigger Neuroinflammatory Activation
Liu, S., Liu, Y., Hao, W., Wolf, L., Kiliaan, A. J., Penke, B., Rübe, C. E., Walter, J., Heneka, M. T., Hartmann, T., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101121 · Cited by 439 · cited 1×
“Additionally, TLR2 deficiency enhanced phagocytosis and clearance of Ab in cultured microglia [54].”
BackgroundLeclercq, S., Mian, F. M., Stanisz, A. M., Bindels, L. B., Cambier, E., Ben-Amram, H., Koren, O., Forsythe, P., & Bienenstock, J. (2017) · Nature Communications · doi:10.1038/ncomms15062 · Cited by 434
Composition and temporal stability of the gut microbiota in older persons
Jeffery, I. B., Lynch, D. B., & O’Toole, P. W. (2016) · The ISME Journal · doi:10.1038/ismej.2015.88 · Cited by 421 · cited 1×
“The diversity and configuration of microbiota in the elderly can be affected by factors including residence location, diet, and health status, leading to the incidence of a wide variety of aging-related diseases [81,82].”
BackgroundSystemic immune challenges trigger and drive Alzheimer-like neuropathology in mice
Krstic, D., Madhusudan, A., Doehner, J., Vogel, P., Notter, T., Imhof, C., Manalastas, A., Hilfiker, M., Pfister, S., Schwerdel, C., et al. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-151 · Cited by 400
Alzheimer's Association Calcium Hypothesis Workgroup, & Khachaturian, Z. S. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.12.006 · Cited by 311
The LPS receptor (CD14) links innate immunity with Alzheimer's disease
Fassbender, K., Walter, S., Kühl, S., Landmann, R., Ishii, K., Bertsch, T., Stalder, A. K., Muehlhauser, F., Liu, Y., Ulmer, A. J., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-0364fje · Cited by 307 · cited 1×
“excessive microglial activation and toxicity [117].”
Richard, K. L., Filali, M., Préfontaine, P., & Rivest, S. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1146-08.2008 · Cited by 298
Minter, M. R., Hinterleitner, R., Meisel, M., Zhang, C., Leone, V., Zhang, X., Oyler-Castrillo, P., Zhang, X., Musch, M. W., Shen, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11047-w · Cited by 292
Song, M., Jin, J., Lim, J.-E., Kou, J., Pattanayak, A., Rehman, J. A., Kim, H.-D., Tahara, K., Lalonde, R., & Fukuchi, K.-I. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-92 · Cited by 273
Nimgampalle, M. (2017) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2017/26106.10428 · Cited by 241
Mancuso, C., & Santangelo, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.009 · Cited by 232 · cited 2×
“Administration of probiotics appears to be a novel and safe method to preserve a healthy intestinal microbiota and intestinal barrier, reducing the initiation of pro-inflammatory responses and propagation of neuroinflammation in neurodegeneration diseases [125].”
BackgroundMethodScreening of innate immune receptors in neurodegenerative diseases: A similar pattern
Letiembre, M., Liu, Y., Walter, S., Hao, W., Pfander, T., Wrede, A., Schulz-Schaeffer, W., & Fassbender, K. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.018 · Cited by 228
Chen, K., Iribarren, P., Hu, J., Chen, J., Gong, W., Cho, E. H., Lockett, S., Dunlop, N. M., & Wang, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508125200 · Cited by 214
Self-citationBecker, L., Nguyen, L., Gill, J., Kulkarni, S., Pasricha, P. J., & Habtezion, A. (2018) · Gut · doi:10.1136/gutjnl-2016-312940 · Cited by 196 · cited 1×
“apoptosis and loss of enteric neurons and neural stem cells [71].”
BackgroundStyren, S. D., Civin, W. H., & Rogers, J. (1990) · Experimental Neurology · doi:10.1016/0014-4886(90)90054-v · Cited by 191
Can a Bacterial Endotoxin be a Key Factor in the Kinetics of Amyloid Fibril Formation?
Asti, A., & Gioglio, L. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131394 · Cited by 180
Kahn, M. S., Kranjac, D., Alonzo, C. A., Haase, J. H., Cedillos, R. O., McLinden, K. A., Boehm, G. W., & Chumley, M. J. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.01.010 · Cited by 177
Scholtzova, H., Kascsak, R. J., Bates, K. A., Boutajangout, A., Kerr, D. J., Meeker, H. C., Mehta, P. D., Spinner, D. S., & Wisniewski, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5715-08.2009 · Cited by 166
Implication of the Immune System in Alzheimer's Disease: Evidence from Genome-Wide Pathway Analysis
Lambert, J.-C., Grenier-Boley, B., Chouraki, V., Heath, S., Zelenika, D., Fievet, N., Hannequin, D., Pasquier, F., Hanon, O., Brice, A., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100018 · Cited by 144
McDonald, C. L., Hennessy, E., Rubio-Araiz, A., Keogh, B., McCormack, W., McGuirk, P., Reilly, M., & Lynch, M. A. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.07.143 · Cited by 108
Qin, Y., Liu, Y., Hao, W., Decker, Y., Tomic, I., Menger, M. D., Liu, C., & Fassbender, K. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600873 · Cited by 90
Scholtzova, H., Do, E., Dhakal, S., Sun, Y., Liu, S., Mehta, P. D., & Wisniewski, T. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1967-16.2016 · Cited by 82 · cited 2×
“Intraperitoneal injection of TLR9 agonist significantly reduced Ab and tau pathologies, as well as levels of toxic oligomers in AD mouse models [64,66,139].”
BackgroundEnhanced susceptibility of triple transgenic Alzheimer’s disease (3xTg-AD) mice to acute infection
Montacute, R., Foley, K., Forman, R., Else, K. J., Cruickshank, S. M., & Allan, S. M. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0826-5 · Cited by 43
Cited by
The microbiota-gut-brain axis: from motility to mood
Margolis, K. G., Cryan, J. F., & Mayer, E. A. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.066 · Cited by 999
Neuroinflammation in Alzheimer’s Disease: Current Progress in Molecular Signaling and Therapeutics
Thakur, S., Dhapola, R., Sarma, P., Medhi, B., & Reddy, D. H. (2023) · Inflammation · doi:10.1007/s10753-022-01721-1 · Cited by 557
“TLRs are able to recognize Aβ42 and release IL-6 and IL-1β along with TNF-α which can be harmful for the neuronal cells [47].”
BackgroundRegulatory role of short-chain fatty acids in inflammatory bowel disease
Zhang, Z., Zhang, H., Chen, T., Shi, L., Wang, D., & Tang, D. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00869-5 · Cited by 259
Toll-like receptor-mediated neuroinflammation: relevance for cognitive dysfunctions
Squillace, S., & Salvemini, D. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.05.004 · Cited by 117
Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer’s Disease
Kang, Y. J., Diep, Y. N., Tran, M., & Cho, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249591 · Cited by 36
Metadata
- Authors
- Lin, C., Zhao, S., Zhu, Y., Fan, Z., Wang, J., Zhang, B., & Chen, Y.
- Venue
- Computational and Structural Biotechnology Journal
- Published
- 2019
- Volume
- 17
- Pages
- 1309-1317
- ISSN
- 2001-0370 (ISSN-L)
- OpenAlex
- W2981755996
- Cited by
- 89
- References
- 61
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.